TrialJournal of clinical hypertension (Greenwich, Conn.)2016

LCZ696, a First-in-Class Angiotensin Receptor-Neprilysin Inhibitor: The First Clinical Experience in Patients With Severe Hypertension.

Kazuomi Kario et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.